Status:

UNKNOWN

Low Dose Doxycycline in the Treatment of Corneal Burn

Lead Sponsor:

Sun Yat-sen University

Conditions:

Eye Burns

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

PHASE3

Brief Summary

To evaluate the safety and efficacy of oral low dose doxycycline in the treatment of corneal burn.

Detailed Description

Severe Ocular Burn often leads to the Ocular surface failure, corneal vascularization dissolved hole or corneal opacity.Because the conventional treatment effect is not ideal, blindness rate is extrem...

Eligibility Criteria

Inclusion

  • age from 18-70 years old, not limited to sex
  • 2\. ocular burn (including chemical injury, thermal burns)
  • 3\. studies of eye with Dua grade (2001) III, within 14 days after burns
  • 4\. about the eye burns
  • become the research with only one eye
  • conform to the standards of subjects for the eyes
  • Choose poor eyesight as in the study
  • If the vision is the same on both sides, the choice classification is higher as the research of eye
  • If the binocular vision and graded at the same time, according to a study in can be determined in consultation with the patient's eye
  • signed informed consent form

Exclusion

  • \- 1. Only one eye function
  • The exclusion criteria of the eye
  • A) corneal thinning depth ≥ 1/2CT, corneal perforation or perforation tendency
  • B, Dua classification I、II、IV、V、VI
  • C) after injury had received eye operation (such as amniotic membrane transplantation or covering)
  • D) Poor control of intraocular pressure after anti-glaucoma drug treatment (IOP ≥ 25mmHg)
  • E) past other corneal diseases
  • F) past ocular history of radiation therapy or eye operation history
  • G) eyelid defect, incomplete eyelid closure, entropion, trichiasis
  • 3\. Any side formulated after secondary infection
  • 4\. Other rule out criteria
  • A) Tetracycline class history of drug allergy
  • B) poor control of blood pressure (defined as after treatment with antihypertensive drugs, blood pressure is 150/95mmHg or higher)
  • C) serious heart, hepatic, renal insufficiency (or myocardial infarction, arrhythmia, myocardial ischemia and cardiac insufficiency, ALT, AST, upper limit of normal or higher by 2.5 times, creatinine upper limit of normal or higher by 1.5 times)
  • D) during pregnancy or lactation women (defined as pregnancy urine pregnancy test results in this test)
  • E) child-bearing age subjects (male and female) is suitable precautions during the entire study
  • F) into the group participated in other clinical subjects before 3 months
  • G) people with TB
  • H) nerve with mental illness

Key Trial Info

Start Date :

September 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2014

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT01886560

Start Date

September 1 2013

End Date

September 1 2014

Last Update

August 9 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Zhongshan Ophthalmic Center

Guangzhou, Guangdong, China, 510060